Oral small-molecule GLP-1 safiglipron cuts HbA1c in phase 3 diabetes trial

Overview

Updated 1 hour ago

Injectable GLP-1 drugs like Ozempic and Wegovy dominate diabetes care, but they require needles, and the only oral option, Rybelsus, demands an empty stomach at dosing. This week, China's Hengrui published phase 3 data for its answer: safiglipron, a once-daily small-molecule pill taken with food.

In 284 patients with early type 2 diabetes, safiglipron cut HbA1c by 1.20 to 1.45 percentage points above placebo, with up to 78% of patients reaching the under-7% glucose target. Gastrointestinal side effects rose sharply with dose, and weight loss stayed modest.

Why it matters

Safiglipron could remove the injection and fasting rules from GLP-1 treatment, widening access to a diabetes drug class millions of patients skip today.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

1.45 p.p.

Placebo-adjusted HbA1c reduction at 90 mg

Top dose cut HbA1c by 1.45 percentage points above placebo at week 32.

77.8%

Patients at 90 mg reaching HbA1c under 7%

Compared with 25.0% on placebo.

−3.56%

Body weight change vs placebo at 90 mg

Weight effect was modest versus orforglipron's 4.5–7.6% in its phase 3 trial.

73.6%

Gastrointestinal adverse events at 90 mg

vs 15.3% on placebo; most were mild to moderate, and most hit during dose titration.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Organizations Involved

Jiangsu Hengrui Pharmaceuticals

Pharmaceutical company

Advancing safiglipron through the phase 3 OUTSTAND program

Developer of safiglipron (HRS-7535), a once-daily oral small-molecule GLP-1 receptor agonist.

Eli Lilly and Company

Pharmaceutical company

Marks orforglipron, the first approved oral small-molecule GLP-1

Competitor whose oral GLP-1 orforglipron posted phase 3 results in 2025.

Novo Nordisk

Pharmaceutical company

Marks Rybelsus, the peptide oral GLP-1 with fasting requirements

Maker of oral semaglutide (Rybelsus), the first oral GLP-1 approved for type 2 diabetes.

Timeline

September 2019 September 2026

4 events Latest: Today

Tap a bar to jump to that date

September 2026
Safiglipron OUTSTAND-1 results published
Today Publication

Placebo-adjusted HbA1c fell 1.20 to 1.45 percentage points; up to 78% of patients hit the under-7% target.
Today
June 2025
orforglipron posts phase 3 results
Competition

Lilly publishes phase 3 data in NEJM, confirming oral small-molecule GLP-1s work (month approximate).
June 1st, 2025
October 2024
OUTSTAND-1 begins enrolling
Trial

284 adults with early type 2 diabetes enter the trial at 46 Chinese sites, randomized to 30, 60, or 90 mg of safiglipron or placebo.
October 21st, 2024
September 2019
FDA approves Rybelsus, the first oral GLP-1
Approval

Oral semaglutide reaches the market but must be taken fasting, with limited water.
September 20th, 2019

Scenarios

China's NMPA approves safiglipron for type 2 diabetes

Likely Resolves by End of 2028

Discussed by: Analysts tracking Hengrui's metabolic pipeline

Hengrui built the OUTSTAND program to support registration. With OUTSTAND-1 positive, the company files with China's NMPA, where the drug was studied. Approval would give China a homegrown, injection-free GLP-1 to compete with imported blockbusters. Global licensing deals would likely follow.

Safiglipron posts phase 3 weight-loss results

Possible Resolves by End of 2028

Discussed by: Observers citing phase 2 obesity data

Phase 2 showed weight loss in adults with obesity. A phase 3 obesity program would test whether the modest weight effect seen at diabetes doses scales up. Strong results would let Hengrui pitch safiglipron against Lilly's orforglipron in the weight-loss market. Weak results would keep it a diabetes-only drug.

Gastrointestinal side effects cap safiglipron's real-world use

Possible Resolves by End of 2029

Discussed by: Concerns raised in the trial's adverse-event profile

GI events hit 73.6% of 90 mg patients, and 6.9% stopped for adverse events at that dose. If real-world persistence mirrors the trial, many patients will tolerate only lower doses, shrinking the efficacy advantage. Payers may steer patients toward alternatives if discontinuation runs high.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

September 2019

Oral semaglutide (Rybelsus) approval (2019)

The FDA approved Rybelsus, Novo Nordisk's oral form of semaglutide, as the first oral GLP-1 for type 2 diabetes. It removed the injection barrier but required patients to take it on an empty stomach with limited water each morning.

Then

Opened the oral GLP-1 market and proved patients would accept an oral option.

Now

Left an access gap: the fasting rule and peptide formulation limited convenience, pushing rivals toward small molecules.

Why this matters now

Safiglipron targets exactly the constraint Rybelsus left in place: a pill that works with food, no fasting needed.

June 2025

Orforglipron phase 3 ATTAIN results (2025)

Lilly published phase 3 data in the NEJM showing its oral small-molecule GLP-1, orforglipron, cut HbA1c by 0.83 to 1.07 percentage points versus placebo and produced weight loss of 4.5% to 7.6% at week 40. It became the first approved oral small-molecule GLP-1 receptor agonist.

Then

Validated that non-peptide oral GLP-1s work without injection or fasting constraints.

Now

Set the benchmark safiglipron is now measured against: comparable glucose control, weaker weight effect here.

Why this matters now

Safiglipron is the direct competitor. Its stronger HbA1c numbers and smaller weight effect define the two drugs' competing profiles.